NCT06217731View on ClinicalTrials.gov

Inflammatory Markers in Saliva of Patients With Burning Mouth Syndrome

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

February 10, 2022

Study Completion Date

December 10, 2023

Conditions
Burning Mouth Syndrome
Interventions
COMBINATION_PRODUCT

Laser+clonazepam

treated with the Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month and Rivotril 0.25mg once every 24 hours for a month

DEVICE

Laser Sham

INACTIVE Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month

DEVICE

Laser

Active Helbo® Theralite Laser 3D Pocket Probe low power diode laser once a week for a month

DRUG

Clonazepam

Rivotril 0.25mg once every 24 hours for a month

Trial Locations (1)

30004

Pia Lopez Jornet, Murcia

All Listed Sponsors
lead

Universidad de Murcia

OTHER

NCT06217731 - Inflammatory Markers in Saliva of Patients With Burning Mouth Syndrome | Biotech Hunter | Biotech Hunter